Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2009

01-08-2009 | Breast Oncology

Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis

Authors: Frank A. Orlando, MD, Kevin D. Brown, PhD

Published in: Annals of Surgical Oncology | Issue 8/2009

Login to get access

Abstract

Breast cancer diversity is histologically evident as various proliferative benign lesions, in situ carcinomas, and invasive carcinomas that may develop into distant metastases. Breast tumor molecular subtypes have been defined by genome-wide expression microarray technology and reveal associations between genetic alterations and the malignant phenotype. Early work has been conducted to use subtype-specific biomarkers to elucidate targeted treatment options early in the course of breast cancer progression. Additionally, DNA methylation is an epigenetic modification that contributes to breast cancer progression by transcriptionally silencing certain tumor suppressor genes. Among the genes characterized as targets for silencing are well-established tumor suppressors such as RASSF1A, RARB, SFN, and TGM2. Measuring elevated gene copy number and aberrant gene promoter methylation can further facilitate characterization of breast tumor molecular subtype; however, profiling of breast tumors based on epigenetic criteria has yet to be established. Epigenomic analysis has been investigated for clinical applicability, and it has great promise when used in combination with minimally invasive techniques for both diagnostic and prognostic purposes.
Literature
1.
Tavassoli FA, Deville P. World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press;2003.
2.
3.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMedCrossRef
4.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRef
5.
Sorlie T, Tibshirani R, Parker J, et al. Repeated observations of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.PubMedCrossRef
6.
Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relelvant subtypes of breast cancer: gene expression analysis across three different platforms. BMC Genomics. 2006;7:127.PubMedCrossRef
7.
Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–50.PubMedCrossRef
8.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295:2492–502.PubMedCrossRef
9.
Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–90.PubMedCrossRef
10.
Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.PubMedCrossRef
11.
Sherene L, Haibe-Kains B, Desmedt C, et al. Predicting prognosis using molecular profiling in estrogen-positive breast cancer treated with tamoxifen. BMC Genomics. 2008;9:239.CrossRef
12.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-85.PubMedCrossRef
13.
Carey LA, Dees EC, Sawyer L, et al. Triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.PubMedCrossRef
14.
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–81.PubMedCrossRef
15.
Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on cytokeratin expression. Histopathology. 2007;50:434–8.PubMedCrossRef
16.
Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.PubMedCrossRef
17.
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef
18.
Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:207–9.CrossRef
19.
Burstein HJ, Storniolo AM, Fanco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19:1068–74.PubMedCrossRef
20.
Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007;8:47–60.PubMedCrossRef
21.
Frassoldati A, Guarneri V, Piacentini F, et al. Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin Breast Cancer. 2008;8:97–100.PubMedCrossRef
22.
Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 2006;13:39–49.PubMedCrossRef
23.
Somiari SB, Shriver CD, He J, et al. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. Cancer Genet Cytogenet. 2004;155:108–18.PubMedCrossRef
24.
Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944–51.PubMedCrossRef
25.
Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007;9:R61.PubMedCrossRef
26.
Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39:655–60.PubMedCrossRef
27.
28.
29.
Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol. 2006;310:251–74.PubMedCrossRef
30.
Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol. 2005;83:296–321.PubMedCrossRef
31.
Zhang Y, Reinberg, D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001;15:2343–60.PubMedCrossRef
32.
33.
Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400.PubMedCrossRef
34.
35.
Lin JC, Jeong S, Liang G, et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell. 2007;12:432–44.PubMedCrossRef
36.
37.
38.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.PubMedCrossRef
39.
40.
Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291–8.PubMedCrossRef
41.
Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213–8.PubMed
42.
Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23:206–15.PubMedCrossRef
43.
Fujisawa K, Maesawa C, Sato R, et al. Epigenetic status and aberrant expression of the maspin gene in human hepato-biliary tract carcinomas. Lab Invest. 2005;85:214–24.PubMedCrossRef
44.
Ting AH, Schuebel KE, Herman JG, Baylin SB. Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet. 2005;37:906–10.PubMedCrossRef
45.
46.
47.
Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681–6.PubMedCrossRef
48.
Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654–9.PubMedCrossRef
49.
Cheng YW, Pincas H, Bacolod MD, et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008;14:6005–13.PubMedCrossRef
50.
51.
Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127–38.PubMedCrossRef
52.
Shaw RJ, Hall GL, Lowe D, et al. CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol. 2007;43:878–86.PubMedCrossRef
53.
Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–9.PubMed
54.
Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59: 5438–42.PubMed
55.
Zhang C, Guo X, Jiang G, et al. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer. 2008;123: 998–1004.PubMedCrossRef
56.
Tanemura A, Terando AM, Sim MS, et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res. 2009;15: 1801–7.PubMedCrossRef
57.
Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003;9: 2912–9.PubMed
58.
Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone status and response to tamoxifen. Cancer Res. 2004;64:3807–13.PubMedCrossRef
59.
Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007;9:R57.
60.
Fiegl H, Millinger S, Goebel G, et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 2006;66:29–33.PubMedCrossRef
61.
Sunami E, Shinozaki M, Sim MS, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 2008;10:R46.PubMedCrossRef
62.
Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–9.PubMed
63.
Bae YK, Brown A, Garrett E, et al. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res. 2004;10:5998–6005.PubMedCrossRef
64.
Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003;107:970–5.PubMedCrossRef
65.
Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002;160: 605–12.PubMed
66.
Tommasi S, Karm DL, Wu X, et al. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. 2009;11: R14.PubMedCrossRef
67.
Pinzone JJ, Stevenson H, Strobl JS, et al. Molecular and cellular determinates of estrogen receptor α expression. Mol Cell Biol. 2004;24:4605–12.PubMedCrossRef
68.
Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res. 1998;58:2515–9.PubMed
69.
Wei M, Xu J, Dignam J, et al. Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in dintinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008;111:113–20.PubMedCrossRef
70.
71.
Catteau A, Harris WH, Xu CF, et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999;18:1957–65.PubMedCrossRef
72.
Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.PubMedCrossRef
73.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8:R38.PubMedCrossRef
74.
Xu X, Gammon MD, Zhang Y, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2008 Jun 3. [Epub ahead of print] PMID: 18521744.
75.
Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126–32.PubMedCrossRef
76.
Matros E, Wang ZC, Lodeiro G, et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179–86.PubMedCrossRef
77.
Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636–44.PubMedCrossRef
78.
Salomon-Vincent A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24.CrossRef
79.
Krop IE, Sgroi D, Porter DA, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA. 2001;98:9796–801.PubMedCrossRef
80.
Krop I, Maguire P, Lahti Domenici J, et al. Lack of HIN-1 methylation in BRCA1-linked and “BRCA1-like” breast tumors. Cancer Res. 2003;63:2024–27.PubMed
81.
Tisserand P, Fouquet C, Barrois M, et al. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther. 2003;2:559–3.PubMed
82.
Pageau GJ, Hall LL, Ganesan S, et al. The disappearing Barr body in breast and ovarian cancers. Nat Rev Cancer. 2007;7:628–33.PubMedCrossRef
83.
84.
Richardson AL, Wang ZC, Nicolo AD, et al. X chromosome abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121–32.PubMedCrossRef
85.
Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400–4.PubMedCrossRef
86.
87.
88.
Pasquali L, Bedeir A, Ringquist S, et al. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett. 2007;257:136–44.PubMedCrossRef
89.
Lodygin D, Hermeking H. The role of epigenetic inactivation of 14-3-3σ in human cancer. Cell Res. 2005;15:237–46.PubMedCrossRef
90.
Umbricht CB, Evron E, Gabrielson E, et al. Hypermethylation of 14-3-3σ is an early event in breast cancer. Oncogene. 2001;20:3348–53.PubMedCrossRef
91.
Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J Natl Cancer Inst. 2000;92:826–32.PubMedCrossRef
92.
93.
Bean GR, Scott V, Yee L, et al. Retinoic acid receptor-β2 promoter methylation in random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev. 2005;14:790–8.PubMedCrossRef
94.
Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp. 2003;70:179–99.PubMed
95.
Ai L, Kim WJ, Kim TY, et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006;66:7899–909.PubMedCrossRef
96.
Ai L, Tao Q, Zhong S, et al. Inactivation of Mnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006;27:1341–8.PubMedCrossRef
97.
Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008;29:510–8.PubMedCrossRef
98.
Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat. 2007;10:144–51.PubMedCrossRef
99.
Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92:404–8.PubMedCrossRef
100.
Lehmann U, Celikkaya G, Hasemeier B, et al. Promoter hypermethylation of the death-associated protine kinase gene in cancer is associated with the invasive lobular subtype. Cancer Res. 2002;62:6634–8.PubMed
101.
Masood S. Cytomorphology as a risk predictor: experience with fine needle aspiration biopsy, nipple fluid aspiration, and ductal lavage. Clin Lab Med. 2005;25:827–43.PubMedCrossRef
102.
Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001;357:1335–6.PubMedCrossRef
103.
Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624–32.PubMed
104.
Visvanathan K, Santor D, Ali SZ, et al. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer – a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev. 2007;16:950–55.PubMedCrossRef
105.
Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res. 2004;10:28–32.PubMedCrossRef
106.
Fackler MJ, McVeigh M, Mehrotra J et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004;64:4442–52.PubMedCrossRef
107.
Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. 2006;12:3306–10.PubMedCrossRef
108.
Euhus DM, Bu D, Ashfaq R, et al. Atypia and DNA methylation in nipple duct lavage in relation to predict breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:1812–21.PubMedCrossRef
109.
Lewis CM, Cler LR, Bu DW, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res. 2005;11:166–72.PubMed
110.
Euhus DM, Bu D, Milchgrub S, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1051–9.PubMedCrossRef
111.
Bean GR, Ibarra Drendall C, Goldenberg VK, et al. Hypermethylation or the breast cancer-associated gene 1 promoter does not predict cytologic atypia of correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:50–6.PubMedCrossRef
112.
Baker JC, Ostrander JH, Lem S, et al. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev. 2008;17:1884–90.PubMedCrossRef
113.
Jeronimo C, Costa I, Martins MC, et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res. 2003;9:3413–7.PubMed
114.
Pu RT, Laitala LE, Alli PM, et al. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol. 2003;16:1095–101.PubMedCrossRef
115.
Jeronimo C, Monteiro P, Henrique R, et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat. 2008;109:27–34.PubMedCrossRef
116.
Dulaimi E, Hillinck J, Ibanez de Caceres I, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res. 2004;10:6189–93.PubMedCrossRef
117.
Muller HM, Widschwendter A, Fiegl H, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003;63:7641–5.PubMed
118.
Martinez-Galan J, Torres B, Del Moral R, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther. 2008;7:958–65.PubMedCrossRef
119.
Snell C, Krypuy M, Wong EM, et al. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008;10:R12.PubMedCrossRef
Metadata
Title
Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis
Authors
Frank A. Orlando, MD
Kevin D. Brown, PhD
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0500-y

Other articles of this Issue 8/2009

Annals of Surgical Oncology 8/2009 Go to the issue

Gastrointestinal tumors

Developing an Institutional Protocol Guideline for Laparoscopy-Assisted Distal Gastrectomy

Radiation Oncology

Is There a Role for Intraoperative Radiation Therapy in Patients with Resected Pancreatic Adenocarcinoma?

Gastrointestinal Oncology

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin

Melanomas

False-Negative Sentinel Node Biopsy

Gastrointestinal Oncology

A Prospective Trial Comparing 1% Lymphazurin vs 1% Methylene Blue in Sentinel Lymph Node Mapping of Gastrointestinal Tumors

Hepatobiliary and Pancreatic Tumors

Relationship Between Microvessel Count and Postoperative Survival in Patients with Intrahepatic Cholangiocarcinoma